[go: up one dir, main page]

BRPI0919073A2 - inibidores de protease - Google Patents

inibidores de protease

Info

Publication number
BRPI0919073A2
BRPI0919073A2 BRPI0919073A BRPI0919073A BRPI0919073A2 BR PI0919073 A2 BRPI0919073 A2 BR PI0919073A2 BR PI0919073 A BRPI0919073 A BR PI0919073A BR PI0919073 A BRPI0919073 A BR PI0919073A BR PI0919073 A2 BRPI0919073 A2 BR PI0919073A2
Authority
BR
Brazil
Prior art keywords
protease inhibitors
protease
inhibitors
Prior art date
Application number
BRPI0919073A
Other languages
English (en)
Inventor
Bertil Samuelsson
Horst Wahling
Perola Johansson
Pia Kahnberg
Vladimir Ivanov
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of BRPI0919073A2 publication Critical patent/BRPI0919073A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0919073A 2008-09-24 2009-09-24 inibidores de protease BRPI0919073A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0817425.2A GB0817425D0 (en) 2008-09-24 2008-09-24 Protease inhibitors
PCT/EP2009/062407 WO2010034789A1 (en) 2008-09-24 2009-09-24 Protease inhibitors

Publications (1)

Publication Number Publication Date
BRPI0919073A2 true BRPI0919073A2 (pt) 2016-03-15

Family

ID=39952075

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919073A BRPI0919073A2 (pt) 2008-09-24 2009-09-24 inibidores de protease

Country Status (10)

Country Link
EP (1) EP2350089A1 (pt)
JP (1) JP2012503626A (pt)
KR (1) KR20110059657A (pt)
CN (1) CN102224155A (pt)
AU (1) AU2009295899A1 (pt)
BR (1) BRPI0919073A2 (pt)
CA (1) CA2738025A1 (pt)
EA (1) EA201170480A1 (pt)
GB (1) GB0817425D0 (pt)
WO (1) WO2010034789A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314503D0 (en) * 2013-08-13 2013-09-25 Medivir Ab Cysteine protease inhibitor salt
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
SE0400022D0 (sv) * 2004-01-08 2004-01-08 Medivir Ab New compounds
GB0614052D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
CA2738025A1 (en) 2010-04-01
AU2009295899A1 (en) 2010-04-01
EP2350089A1 (en) 2011-08-03
CN102224155A (zh) 2011-10-19
KR20110059657A (ko) 2011-06-02
GB0817425D0 (en) 2008-10-29
WO2010034789A1 (en) 2010-04-01
JP2012503626A (ja) 2012-02-09
EA201170480A1 (ru) 2011-12-30

Similar Documents

Publication Publication Date Title
CY2020023I2 (el) Αναστολεiς βητα-λακταμασων
LTC2178888I2 (lt) Proteazomos inhibitoriai
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
EP2305306A4 (en) NEURO INVASION INHIBITOR
EP2260108A4 (en) PROTEASE ASSAY
BRPI0917808A2 (pt) inibidores de cmet
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
BRPI0918564A2 (pt) inibidores
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
BRPI0814797A2 (pt) Inibidores dna-pk
BRPI1011267A2 (pt) inibidores de protease
EP2393898A4 (en) DUST SUPPRESSORS
EP2374802A4 (en) INHIBITOR OF KYNURENINE PRODUCTION
DK2066662T3 (da) Serinhydrolaseinhibitorer
DK2240506T3 (da) IAP inhibitorer
BRPI0922283A2 (pt) inibidores da cistéina protease
EP2313426A4 (en) NEW PROTEASE INHIBITORS
BRPI0918966A2 (pt) inibidores de protease
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
BRPI0919073A2 (pt) inibidores de protease
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
TH0801000834A (th) ตัวยับยั้งเฮเทอโรไซคลิก แอสพาร์ทิลโปรตีเอส

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired